Journal article icon

Journal article

Reducing hyperglucagonemia in type 2 diabetes using low dose Glibenclamide: results of the LEGEND-A pilot study

Abstract:

Fasting hyperglucagonemia is a key feature of type 2 diabetes (T2D), which leads to increased hepatic glucose production and exacerbates hyperglycemia. Preclinical studies have shown that low concentrations of sulfonylureas can partially restore appropriate glucose-regulated glucagon secretion in islets from donors with T2D. In this pilot clinical trial, sixteen participants with T2D (diet controlled or on metformin alone) underwent a 4-week open-label, non-randomized, dose-titration (0.3–6mg...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1111/dom.14740

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Oxford college:
Harris Manchester College
Role:
Author
ORCID:
0000-0003-4171-9612
Publisher:
Wiley Publisher's website
Journal:
Diabetes, Obesity and Metabolism Journal website
Volume:
24
Issue:
8
Pages:
1671-1675
Publication date:
2022-05-18
Acceptance date:
2022-04-28
DOI:
EISSN:
1463-1326
ISSN:
1462-8902
Language:
English
Keywords:
Pubs id:
1255584
Local pid:
pubs:1255584
Deposit date:
2022-05-04

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP